Remote Results of Treatment of Patients with Colorectal Cancer against the Background of Inflammatory Bowel Diseases

To compare overall and relapse-free survival of patients with sporadic colorectal cancer (CRC) and patients with CRC associated with inflammatory bowel disease (IBD).

in a group of patients with CRC and IBD (n=17) and a group of patients with sporadic CRC (n=17), the overall and relapse-free survival rates, perioperative parameters (complications, number of removed and affected lymph nodes, duration of hospitalization in the postoperative period) were assessed.

patients in both groups did not differ statistically significantly in the duration of surgery, volume of intraoperative blood loss, frequency of postoperative complications and duration of hospitalization. No significant differences in the progression of oncological disease were found. Overall survival for 1 year was 100% in the group of patients with CRC and IBD and 94.2% in the group with sporadic CRC, relapse-free survival was 71 and 79%, respectively, and cancer-specific survival was 100% in both groups. The predicted 3-year indicators were 68 and 94.2% for overall survival, 75 and 79% for relapse-free survival, 68 and 100% for cancer-specific survival in the CRC and IBD groups and with sporadic CRC, respectively. According to the obtained data, IBD is not an unfavorable factor for overall and cancer-specific survival in patients with CRC: clinical characteristics, perioperative data and oncologic outcomes in patients with CRC and IBD did not differ from those in patients with sporadic CRC. Previous studies on the oncologic outcome of IBD-associated CRC and sporadic CRC have shown conflicting results, which may be due to the use of non-representative databases. Our study is also limited by a small number of patients, follow-up time and retrospective single-center design, which allows only preliminary conclusions.

Clinical outcomes in patients with CRC and IBD are similar to those in patients with sporadic CRC. The impact of IBD on long-term oncological outcomes remains an open question. Multicenter studies and accumulation of clinical data are needed.